← Back to Evidence Atlas
E2 ModerateModerate confidencePEM ✓LongitudinalPeer-reviewedMachine draft
Standard · 3 min

One-year follow-up of young people with ME/CFS following infectious mononucleosis by Epstein-Barr virus.

Pricoco, Rafael, Meidel, Paulina, Hofberger, Tim et al. · Frontiers in pediatrics · 2023 · DOI

Quick Summary

This study followed 25 young people (12 teenagers and 13 young adults) who developed ME/CFS after having infectious mononucleosis caused by Epstein-Barr virus. Researchers checked on their symptoms and quality of life at the start, 6 months, and 12 months later. Teenagers showed better improvement over the year, with more than half no longer meeting ME/CFS criteria, while young adults continued to have severe symptoms with little improvement.

Why It Matters

This study provides rare longitudinal evidence that ME/CFS triggered by EBV has significantly different outcomes depending on age at onset, suggesting adolescents may have better recovery potential than adults. The finding of a median 13.8-month diagnostic delay highlights critical gaps in medical recognition and supports the urgent need for better diagnostic tools and targeted treatments.

Observed Findings

  • 54% of adolescents (6/12) no longer met ME/CFS diagnostic criteria after one year, compared to 0% of young adults (0/13).
  • Median time from symptom onset to ME/CFS diagnosis was 13.8 months (range: 9.1-34.9), indicating substantial diagnostic delay.
  • Young adults showed progressive worsening in fatigue severity, physical functioning, mental functioning, and health-related quality of life throughout the study year.
  • EBV serology levels and EBV DNA load did not correlate with distinct clinical features of ME/CFS.
  • Standard clinical chemistry showed no evidence of active inflammation in either age group.

Inferred Conclusions

  • Age at ME/CFS onset is a significant prognostic factor, with adolescents having substantially better recovery prospects than young adults.
  • Current diagnostic and laboratory approaches are insufficient for early case identification and cannot distinguish ME/CFS severity or trajectory using standard biomarkers.
  • Conventional medical care provides limited therapeutic benefit, particularly for adult patients, necessitating development of targeted interventions.

Remaining Questions

  • What biological or physiological mechanisms explain the marked difference in prognosis between adolescents and young adults?
  • What specific biomarkers or diagnostic tools could enable earlier identification of ME/CFS after EBV infection?
  • Do long-term outcomes continue to diverge by age beyond the 12-month follow-up period, and what factors predict recovery in adolescents?
  • What therapeutic approaches might improve outcomes in young adults with IM-triggered ME/CFS?

What This Study Does Not Prove

This study does not establish that EBV causes ME/CFS in all cases, only that it can trigger the condition in some young people. The lack of inflammatory markers and EBV correlation does not prove absence of biological dysfunction—it may reflect current limitations in detecting relevant pathophysiology. The small sample size and single-center design limit generalizability to broader populations.

Topics

BiomarkersPost-Exertional Malaise

Tags

Symptom:Post-Exertional MalaiseCognitive DysfunctionPainFatigue
Biomarker:Blood Biomarker
Phenotype:Infection-TriggeredSeverePediatric
Method Flag:No ControlsSmall SampleStrong Phenotyping

Metadata

DOI
10.3389/fped.2023.1266738
PMID
38304441
Review status
Machine draft
Evidence level
Single-study or moderate support from human research
Last updated
7 April 2026